144 related articles for article (PubMed ID: 32526448)
21. What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies.
Leucht S; Fennema H; Engel RR; Kaspers-Janssen M; Lepping P; Szegedi A
J Affect Disord; 2017 Mar; 210():287-293. PubMed ID: 28068617
[TBL] [Abstract][Full Text] [Related]
22. Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorder.
Rashidian H; Subramaniapillai M; Park C; Lipsitz O; Zuckerman H; Teopiz K; Cao B; Lee Y; Gill H; Ho R; Lin K; Rodrigues NB; Iacobucci M; Rosenblat JD; McIntyre RS; Mansur RB
J Affect Disord; 2021 Mar; 282():448-453. PubMed ID: 33422821
[TBL] [Abstract][Full Text] [Related]
23. Perceived sleep quality predicts cognitive function in adults with major depressive disorder independent of depression severity.
Cha DS; Carmona N; Cha RH; Zhou AJ; Subramaniapillai M; Mansur RB; Lee Y; Lee JH; Lee J; Almatham F; Alageel A; Rosenblat JD; Shekotikhina M; Rong C; Harrison J; McIntyre RS
Ann Clin Psychiatry; 2019 Feb; 31(1):17-26. PubMed ID: 30372511
[TBL] [Abstract][Full Text] [Related]
24. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder.
Cao B; Park C; Subramaniapillai M; Lee Y; Iacobucci M; Mansur RB; Zuckerman H; Phan L; McIntyre RS
Front Psychiatry; 2019; 10():17. PubMed ID: 30766492
[No Abstract] [Full Text] [Related]
25. S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial.
Sarris J; Murphy J; Stough C; Mischoulon D; Bousman C; MacDonald P; Adams L; Nazareth S; Oliver G; Cribb L; Savage K; Menon R; Chamoli S; Berk M; Ng CH; Byrne GJ
Psychopharmacology (Berl); 2020 Jan; 237(1):209-218. PubMed ID: 31712971
[TBL] [Abstract][Full Text] [Related]
26. Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database.
Kraus C; Kautzky A; Watzal V; Gramser A; Kadriu B; Deng ZD; Bartova L; Zarate CA; Lanzenberger R; Souery D; Montgomery S; Mendlewicz J; Zohar J; Fanelli G; Serretti A; Kasper S
J Affect Disord; 2023 Aug; 335():349-357. PubMed ID: 37196934
[TBL] [Abstract][Full Text] [Related]
27. Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial.
Otte C; Chae WR; Nowacki J; Kaczmarczyk M; Piber D; Roepke S; Märschenz S; Lischewski S; Schmidt S; Ettrich B; Grabe HJ; Hegerl U; Hinkelmann K; Hofmann T; Janowitz D; Junghanns K; Kahl KG; Klein JP; Krueger THC; Leicht G; Prvulovic D; Reif A; Schoettle D; Strauss M; Westermair A; Friede T; Gold SM
BMJ Open; 2020 Dec; 10(12):e040119. PubMed ID: 33262189
[TBL] [Abstract][Full Text] [Related]
28. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
29. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
30. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder.
Lam RW; Iverson GL; Evans VC; Yatham LN; Stewart K; Tam EM; Axler A; Woo C
J Affect Disord; 2016 Oct; 203():55-61. PubMed ID: 27280963
[TBL] [Abstract][Full Text] [Related]
31. Reliability and Validity of THINC-it in Evaluating Cognitive Function of Patients with Bipolar Depression.
Zhang W; Zhu N; Lai J; Liu J; Ng CH; Chen J; Qian C; Du Y; Hu C; Chen J; Hu J; Wang Z; Zhou H; Xu Y; Fang Y; Shi C; Hu S
Neuropsychiatr Dis Treat; 2020; 16():2419-2428. PubMed ID: 33116541
[TBL] [Abstract][Full Text] [Related]
32. Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder.
Lin CH; Chen CC; Wong J; McIntyre RS
J Affect Disord; 2014 Jun; 161():123-6. PubMed ID: 24751319
[TBL] [Abstract][Full Text] [Related]
33. Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions - Improvement (CGI-S) scale in bipolar and major depressive disorder.
Mohebbi M; Dodd S; Dean OM; Berk M
Eur Psychiatry; 2018 Sep; 53():17-22. PubMed ID: 29859377
[TBL] [Abstract][Full Text] [Related]
34. Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial.
Dean OM; Kanchanatawan B; Ashton M; Mohebbi M; Ng CH; Maes M; Berk L; Sughondhabirom A; Tangwongchai S; Singh AB; McKenzie H; Smith DJ; Malhi GS; Dowling N; Berk M
Aust N Z J Psychiatry; 2017 Aug; 51(8):829-840. PubMed ID: 28578592
[TBL] [Abstract][Full Text] [Related]
35. Metabolic variables associated with response to cognitive behavioural therapy for depression in females: A Canadian biomarker integration network for depression (CAN-BIND) study.
Jones BDM; Levitan RD; Wang W; Uher R; Rotzinger S; Foster JA; Kennedy SH; Farzan F; Quilty LC; Kloiber S
J Psychiatr Res; 2021 Oct; 142():321-327. PubMed ID: 34419752
[TBL] [Abstract][Full Text] [Related]
36. Neurocognitive subgroups in major depressive disorder.
Martin DM; Wollny-Huttarsch D; Nikolin S; McClintock SM; Alonzo A; Lisanby SH; Loo CK
Neuropsychology; 2020 Sep; 34(6):726-734. PubMed ID: 32324004
[TBL] [Abstract][Full Text] [Related]
37. Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations.
Milaneschi Y; Lamers F; Peyrot WJ; Baune BT; Breen G; Dehghan A; Forstner AJ; Grabe HJ; Homuth G; Kan C; Lewis C; Mullins N; Nauck M; Pistis G; Preisig M; Rivera M; Rietschel M; Streit F; Strohmaier J; Teumer A; Van der Auwera S; Wray NR; Boomsma DI; Penninx BWJH;
JAMA Psychiatry; 2017 Dec; 74(12):1214-1225. PubMed ID: 29049554
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
39. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
40. Association of obesity with cognitive function and brain structure in patients with major depressive disorder.
Hidese S; Ota M; Matsuo J; Ishida I; Hiraishi M; Yoshida S; Noda T; Sato N; Teraishi T; Hattori K; Kunugi H
J Affect Disord; 2018 Jan; 225():188-194. PubMed ID: 28837952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
